Early eGFR Dip Likely Doesn't Hinder SGLT2 Inhibitor's Kidney Benefits

(MedPage Today) — The SGLT2 inhibitor empagliflozin (Jardiance) reduced the risk of creatinine increases and acute kidney injury (AKI) even in those with an early dip in estimated glomerular filtration rate (eGFR), according to a meta-analysis…

Source link : https://www.medpagetoday.com/meetingcoverage/era/115988

Author :

Publish date : 2025-06-10 13:25:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30	31

Early eGFR Dip Likely Doesn’t Hinder SGLT2 Inhibitor’s Kidney Benefits

Research Links Affluence to Higher Scarring Alopecia Risk

NIH Halts DEI Policy; Over-the-Counter Ivermectin; Zicam, Orajel Product Recall

Related Posts

Private-Equity Raises Colonoscopy Costs but Not Quality

CAC of Zero? Try to Keep It That Way

Repairing the Aging Blood-Brain Barrier: Real Possibilities

Meltwater bursts through Greenland ice in first-of-a-kind eruption

Wives of Farm Pesticide Applicators at Risk for Incident RA

Walking and Diet Boost Cognition in At-Risk Adults

Private-Equity Raises Colonoscopy Costs but Not Quality

CAC of Zero? Try to Keep It That Way

Repairing the Aging Blood-Brain Barrier: Real Possibilities

Wives of Farm Pesticide Applicators at Risk for Incident RA

Walking and Diet Boost Cognition in At-Risk Adults

Rust-based battery connects to an electricity grid for the first time

GLP-1 Users May Face Optic Nerve Damage Risk in First Year

Best Hospitals Ranked for Gastroenterology and GI Surgery

Categories

Archives